Erythropoietic Protoporphyria: Phase 2 Clinical Trial Results Evaluating the Safety and Effectiveness of Dersimelagon (MT-7117), an Oral MC1R Agonist

被引：11
|
作者：
Balwani, Manisha
Bonkovsky, Herbert L.
Belongie, Kirstine J.
Anderson, Karl E.
Takahashi, Fumihiro
Irizarry, Antonio
Amster, Mark
Bissell, D. Montgomery
Wang, Bruce
Hazan, Lydie
Parker, Charles J.
Cordasco, Edward
Levy, Cynthia
Desnick, Robert J.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-142467
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 10 条
  • [1] Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist
    Ogasawara, Akihito
    Ogawa, Kei
    Ide, Ryosuke
    Ikenaga, Yuka
    Fukunaga, Chie
    Nakayama, Satoshi
    Tsuda, Minoru
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (06) : 801 - 813
  • [2] Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist
    Akihito Ogasawara
    Kei Ogawa
    Ryosuke Ide
    Yuka Ikenaga
    Chie Fukunaga
    Satoshi Nakayama
    Minoru Tsuda
    European Journal of Clinical Pharmacology, 2023, 79 : 801 - 813
  • [3] Dersimelagon, a melanocortin-1 receptor agonist, maintains efficacy regardless of seasons in subjects with erythropoietic protoporphyria: Results from a post hoc analysis of phase 2 clinical trial data
    Belongie, Kirstine
    Takahashi, Fumihiro
    Mukai, Sakiko
    Endou, Mai
    Desnick, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB156 - AB156
  • [4] Efficacy and Safety of Xanomeline, a M1/M4 Receptor Preferencing Agonist, Plus Trospium, a Peripheral Muscarinic Antagonist, in Schizophrenia: Phase 2 Clinical Trial Results
    Brannan, Stephen
    Sawchak, Sharon
    Miller, Andrew
    Paul, Steven M.
    Breier, Alan
    BIOLOGICAL PSYCHIATRY, 2020, 87 (09) : S169 - S169
  • [5] LONG-TERM RESPONSE TO ORAL ELIGLUSTAT IN TREATMENT-NAIVE ADULTS WITH GAUCHER DISEASE TYPE 1: FINAL EFFICACY AND SAFETY RESULTS FROM A PHASE 2 CLINICAL TRIAL AFTER 8 YEARS OF TREATMENT
    Lukina, E.
    Watman, N.
    Dragosky, M.
    Lau, H.
    Avila Arreguin, E.
    Rosenbaum, H.
    Wu, Y.
    Gaemers, S.
    Peterschmitt, M. J.
    HAEMATOLOGICA, 2017, 102 : 290 - 290
  • [6] Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naive Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China
    Xu, Xiaoyuan
    Feng, Bo
    Guan, Yujuan
    Zheng, Sujun
    Sheng, Jifang
    Yang, Xingxiang
    Ma, Yuanji
    Huang, Yan
    Kang, Yi
    Wen, Xiaofeng
    Li, Jun
    Tan, Youwen
    He, Qing
    Xie, Qing
    Wang, Maorong
    Anl, Ping
    Gong, Guozhong
    Liu, Huimin
    Nine, Qin
    Hua, Rui
    Ning, Bo
    Xie, Wen
    Zhang, Jiming
    Huang, Wenxiang
    Yang, Yongfeng
    Lin, Minghua
    Zhao, Yingren
    Yu, Yanhong
    Jia, Jidong
    Yang, Dongliang
    Chen, Liang
    Ye, Yinong
    Nan, Yuemin
    Gong, Zuojiong
    Zhang, Quan
    Hu, Peng
    Wang, Fusheng
    Li, Yongguo
    Li, Dongliang
    Jia, Zhansheng
    Hou, Jinlin
    Chen, Chengwei
    Wu, Jinzi J.
    Wei, Lai
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2019, 7 (03) : 213 - 220
  • [7] Long-term treatment response based on severity of Gaudier disease type 1 at baseline after 8 years of treatment with oral eliglustat: Final efficacy and safety results from a phase 2 clinical trial in treatment-naive adult patients
    Lau, Heather A.
    Lukina, Elena
    Watman, Nora
    Dragosky, Marta
    Avila Arreguin, Elsa
    Rosenbaum, Hanna
    Wu, Yaoshi
    Gaemers, Sebastiaan J. M.
    Peterschmitt, M. Judith
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S83 - S83
  • [8] The Guard1 clinical trial - A first in-human, phase 1/2 study evaluating AVR-RD-02, a hematopoietic stem cell (HSC) gene therapy for Gaucher disease: Preliminary safety, pharmacodynamic and clinical efficacy results from the subjects observed for up to 24 months post-infusion
    Adera, Mathews
    Veselinovic, Milena
    Treohan, Anita
    Golipour, Azadeh
    Ridha, Essra
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 3 - 4
  • [9] Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China
    Wei, Lai
    Xu, Xiaoyun
    Guan, Yujuan
    Zheng, Sujun
    Sheng, Jifang
    Yang, Xingxiang
    Ma, Yuanji
    Huang, Yan
    Kang, Yi
    Wen, Xiaofeng
    Li, Jun
    Tan, Youwen
    He, Qing
    Xie, Qing
    Wang, Maorong
    An, Ping
    Gong, Guozhong
    Liu, Huimin
    Ning, Qin
    Hua, Rui
    Ning, Bo
    Xie, Wen
    Zhang, Jiming
    Huang, Wenxiang
    Yang, Yongfeng
    Lin, Minghua
    Zhao, Yingren
    Yu, Yanhong
    Jia, Jidong
    Yang, Dongliang
    Chen, Liang
    Ye, Yinong
    Nan, Yuemin
    Gong, Zuojiong
    Zhang, Quan
    Hu, Peng
    Wang, FuSheng
    Li, Yongguo
    Li, Dongliang
    Jia, Zhansheng
    Hou, Jinlin
    Chen, Chengwei
    Wu, Jinzi
    HEPATOLOGY, 2018, 68 : 584A - 584A
  • [10] The safety and tolerability of AR101, an oral immunotherapy (OIT) pharmaceutical formulation for peanut allergy, after more than 1 year of treatment: results from an ongoing phase 2b clinical trial (ARC002), including low-dose (300 mg/day) and high-dose (2000 mg/day) maintenance regimens
    Rachid, R. A.
    Bird, J. A.
    Spergel, J. M.
    Jones, S. M.
    Assa'ad, A. H.
    Vickery, B.
    Wang, J.
    Leonard, S. A.
    Laubach, S. S.
    Kim, E. H.
    Davis, B. P.
    Welch, M. J.
    Heimall, J.
    Cianferoni, A.
    MacGinnitie, A. J.
    Crestani, E.
    Bennett, S.
    Elfont, R. M.
    Burks, A. W.
    ALLERGY, 2016, 71 : 105 - 105
1